Scarica l'app Stockscreener
336.75
1.09%
-3.72
Dopo l'orario di chiusura:
336.75
Praxis Precision Medicines Inc Borsa (PRAX) Ultime notizie
How Investors Are Reacting To Praxis (PRAX) Wider Losses, Fresh NDAs And Multi‑Year Cash Runway - simplywall.st
Praxis Precision Medicines (NASDAQ:PRAX) Raised to Strong-Buy at Wolfe Research - MarketBeat
Assessing Praxis Precision Medicines (PRAX) Valuation After Strong Recent Share Price Momentum - simplywall.st
Wolfe Research initiates Praxis stock with outperform rating - Investing.com
Wolfe Research initiates Praxis stock with outperform rating By Investing.com - Investing.com India
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year - AOL.com
Wolfe Research Initiates Coverage of Praxis Precision Medicines (PRAX) with Outperform Recommendation - Nasdaq
Wolfe Research Initiates Coverage on Praxis Precision Medicine (PRAX) | PRAX Stock News - GuruFocus
A Look At Praxis Precision Medicines (PRAX) Valuation After Recent Share Price Momentum - Yahoo Finance
3,826 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by ProShare Advisors LLC - MarketBeat
Praxis NDAs And FDA Designations Put Focus On Valuation Upside - Yahoo! Finance Canada
Praxis Precision Medicines Maps Aggressive Path to Market - TipRanks
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million - Yahoo Finance
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million - The Motley Fool
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress - AOL.com
Praxis Medicines Q4 2025 Earnings Call Transcript - AOL.com
Praxis Precision Medicines (NASDAQ:PRAX) Sets New 12-Month High Following Analyst Upgrade - Defense World
PRAX Stock: Wells Fargo Raises Price Target to $305 | PRAX Stock News - GuruFocus
Praxis Precision shares rally on price target hikes: Analyst sees upside as high as 100% for stock - MSN
Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock - Asianet Newsable
Praxis Precision Medicines stock reaches 52-week high at 337.01 USD - Investing.com
Baird Raises Price Target for PRAX to $433, Maintains Outperform Rating | PRAX Stock News - GuruFocus
Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results - Benzinga
Praxis Precision Medicines Stock Surges on FDA Momentum - TipRanks
Praxis Precision Medicines (NASDAQ:PRAX) Sets New 1-Year High Following Analyst Upgrade - MarketBeat
Truist Financial Forecasts Strong Price Appreciation for Praxis Precision Medicines (NASDAQ:PRAX) Stock - MarketBeat
Deutsche Bank Raises Price Target on Praxis Precision Medicines to $412 From $357, Keeps Buy Rating - marketscreener.com
Wedbush Raises Price Target for PRAX to $130 Despite 'Underperfo - GuruFocus
Wedbush Issues Positive Forecast for Praxis Precision Medicines (NASDAQ:PRAX) Stock Price - MarketBeat
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q4 2025 Earnings Call Transcript - Insider Monkey
Praxis Precision Medicines, Inc (PRAX) Stock Analysis: A Biotech Pioneer with an 80.92% Potential Upside - DirectorsTalk Interviews
Praxis Therapeutics: Advancing Late-Stage Neurology Pipeline Toward Commercialization with Multibillion-Dollar Market Potential - TipRanks
Earnings call transcript: Praxis Precision Q4 2025 misses EPS forecast By Investing.com - Investing.com Canada
Decoding Praxis Precision Medicines Inc (PRAX): A Strategic SWOT Insight - GuruFocus
Praxis Precision Medicines, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Praxis Precision Medicines Inc (PRAX) Q4 2025 Earnings Call Highlights: Strong Financial ... By GuruFocus - Investing.com Canada
Praxis Precision Medicines Inc (PRAX) Q4 2025 Earnings Call High - GuruFocus
Truist reiterates Praxis Precision Medicines stock rating on pricing potential By Investing.com - Investing.com Nigeria
Praxis Precision Medicines (NASDAQ:PRAX) Posts Earnings Results, Misses Estimates By $0.50 EPS - MarketBeat
Truist reiterates Praxis Precision Medicines stock rating on pricing potential - Investing.com South Africa
Praxis Precision Medicines Q4 Earnings Call Highlights - MarketBeat
PRAX: NDAs filed for two CNS drugs; strong cash position funds operations into 2028 - TradingView
Earnings call transcript: Praxis Precision Q4 2025 misses EPS forecast - Investing.com
PRAX: Two NDAs submitted and strong cash position support commercial transition and pipeline progress - TradingView
Praxis Precision Medicines Q4 2025 Earnings Call Transcript - MarketBeat
Praxis Precision Medicines Q4 Net Loss Widens - marketscreener.com
PRAX: Net loss rose to $303.3M in 2025; cash reserves and pipeline support operations into 2028 - TradingView
Earnings Flash (PRAX) Praxis Precision Medicines Posts Q4 Loss $3.50 a Share, vs. FactSet Est of $2.88 Loss - marketscreener.com
Praxis Precision Medicines, Inc. (Praxis) recently disclosed the company's operational progress and financial report for the fourth quarter and full year of 2025. - Bitget
Earnings Breakdown: Praxis Precision Medicine Q4 - Benzinga
PRAX: Two NDAs submitted, commercial launch prep underway, and cash runway extends into 2028 - TradingView
Praxis Precision Medicines Provides Corporate Update and - GlobeNewswire
Praxis Precision Medicines, Inc. (PRAX) Gains Analyst Confidence With Ulixacaltamide - Finviz
1.18%
0.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):